Zhang Feng-Lin, Gao Er-Yun, Shu Rong-Bao, Wang Hui, Zhang Yan, Sun Peng, Li Min, Tang Wei, Jiang Bang-Qin, Chen Shuang-Qi, Cui Fang-Bo
Department of Oncology, Maanshan City People's Hospital, Maanshan, China E-mail :
Asian Pac J Cancer Prev. 2015;16(15):6765-8. doi: 10.7314/apjcp.2015.16.15.6765.
To study the effectiveness of human recombinant endostatin injection (Endostar®) combined with cisplatin doublets in treating advanced non-small cell lung cancer (NSCLC), and to evaluate outcome by CT perfusion imaging.
From April 2011 to September 2014, 76 patients with advanced NSCLC who were treated with platinum-based doublets were divided into group A (36 patients) and group B (40 patients). Endostar® 15 mg/day was administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A, and combined with chemotherapy from the first day in Group B. Endostar® in the two groups was injected intravenously for 14 days.
Treatment effectiveness in the two groups differed with statistical significance (p<0.05). Effectiveness evaluated by CT perfusion imaging, BF, BV, MTT and PS also demonstrated significant differences (all p<0.05). Adverse reactions in the two groups did not significantly vary (p>0.05).
The response rate with Endostar® administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A was better than Endostar® combined with chemotherapy from the first day, and CT perfusion imaging could be a reasonable method for evaluation of patient outcomes.
研究重组人血管内皮抑素注射液（恩度）联合含铂双药方案治疗晚期非小细胞肺癌（NSCLC）的疗效，并通过CT灌注成像评估疗效。
2011年4月至2014年9月，76例接受铂类双药方案治疗的晚期NSCLC患者分为A组（36例）和B组（40例）。A组在化疗前4天给予恩度15 mg/天，从第5天起联合化疗；B组从第1天起联合化疗。两组恩度均静脉注射14天。
两组治疗效果差异有统计学意义（p<0.05）。CT灌注成像评估的疗效，包括BF、BV、MTT和PS也有显著差异（均p<0.05）。两组不良反应无显著差异（p>0.05）。
A组化疗前4天给予恩度并从第5天起联合化疗的有效率优于从第1天起联合化疗，CT灌注成像可为评估患者疗效的合理方法。
